Abstract: The present invention refers to monoclonal antibodies or fragments thereof which are binding to the protein P of the human Respiratory Syncytial Virus (RSV) which comprise a variable region of the heavy chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID 5 or a variable region of the light chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No:2 or SEQ ID No: 6. The invention provides also diagnostic methods ex vivo or in vitro for detection of the viral antigen P of RSV, in which are used the monoclonal antibodies produced and secreted by the hybridomas 2E6/D2 and 6H5/H1. The invention can be used in detection for RSV kits, comprising the antibodies produced by the mentioned hybridomas.

Abstract: The invention relates to an autonomous robotic system, for automatically monitoring the state of shelves in shops, which comprises: a mobile robot made up of a body which comprises: a mobile base that comprises a drive system connected to movement and steering means; an upper structure provided for housing sensors, at least one processing unit and communications means, in which said sensors comprise: at least one laser sensor; at least one distance, depth or proximity sensor; and at least one image sensor; a navigation system in communication with at least one laser sensor, with at least one image sensor, with at least one distance or proximity sensor and with at least one processor; a recognition system in communication with at least one image sensor, with at least one distance or proximity sensor, with at least one processing unit and with the communication means; and a multi-objective planning system in communication with at least one processing unit and with the navigation system.

Abstract: The present invention refers to monoclonal antibodies, or fragments thereof, which recognize the pIII protein of the Adenovirus (ADV), useful for developing diagnostic methods of ADV infection in humans. Particularly, it refers to a monoclonal antibody or fragment thereof comprising a variable region of the heavy chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID No: 5 and a variable region of the light chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 2 or SEQ ID No: 6. It also is addressed to the nucleotide sequences which define said antibodies, in vitro and/or ex vivo diagnostic methods of ADV infection in a biological sample using said monoclonal antibodies, and diagnostic kits for detecting ADV comprising at least one monoclonal antibody against ADV according to the above description.

Abstract: The present invention consist of an aroma recovery system in an installation with a plurality of fermentation vats for preparing beverages such as white wine, red wine, beers and juices to apply a method of recovering aroma from said fermentation vats; said system comprises at least one connection system, and at least one aroma recovery equipment, wherein said connection system comprises control means such a logic controller (PLC). It is also provided a multiple connection system for connecting said plurality of fermentation vats and said aroma recovery equipment by automatic valves and a method of recovering aroma from fermentation vats of a beverage such as, for example, white wine, red wine, beer and juices.

Abstract: The present invention is a aroma recovery equipment from gases exhausted of fermentation vats comprising a first recovery group (100) comprising a first condenser (110) operating at a first temperature of recovered aromas; one second recovery group (200) comprising a second condenser (210) operating at a second temperature of recovered aromas; a cooling group (300) to provide cold by a cooling fluid (301) to said first recovery group (100) via a first fluid connection (302) and to said second recovery group (200) via a second fluid connection (303); control means (400) configured to coordinately control the temperature of said first recovery group (100) and the temperature of said second recovery group (200); and a mobile housing (500) containing said first recovery group (100), said second recovery group (200), said cooling group (300) and said control means (400).

Abstract: The present invention provides dignostic assays for identifying thyroid cancer in a biological sample, including a fine needle aspirate, as well as related compositions and kits useful in practicing the methods of the invention.

Abstract: The present invention refers to monoclonal antibodies, or fragments thereof, which recognize the pIII protein of the Adenovirus (ADV), useful for developing diagnostic methods of ADV infection in humans. Particularly, it refers to a monoclonal antibody or fragment thereof comprising a variable region of the heavy chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID No: 5 and a variable region of the light chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 2 or SEQ ID No: 6. It also is addressed to the nucleotide sequences which define said antibodies, in vitro and/or ex vivo diagnostic methods of ADV infection in a biological sample using said monoclonal antibodies, and diagnostic kits for detecting ADV comprising at least one monoclonal antibody against ADV according to the above description.

Abstract: A medical simulator of procedures associated with punctures, for simulation and practical training in puncture interventions, the medical simulator comprising a phantom, an intervention device and a processing system in data communication with the phantom and the intervention device, wherein the phantom comprises at least one target structure arranged for the training of the intervention and means for detecting the intervention device, said detection means being in communication of data with the processing system. The intervention device comprises a real puncture instrument that includes sensing means and detection means in data communication with the processing system. The phantom comprises a structure with at least two components, a simulation assembly that simulates the behavior of tissues and anatomical structures, and a base structure that forms the phantom support, wherein the base structure comprises accommodation and fixation means to house and fix the simulation assembly.

Abstract: The present invention relates to an immunogenic formulation to be used in mammals against human Metapneumovirus (hMPV), consisting of a lyophilisate of 1×109 ufc/ml of recombinant BCG that expresses the viral protein P of hMPV (of genogroups A1, A2, B1 and B2). The vaccine is derived from the full or partial product of the P gene of hMPV, capable of being used, stabilised and administered in solution without requiring adjuvants. The preparation can also contain combinations of the aforementioned formulations. The formulation is stabilised by means of lyophilisation (conservation range of between 4° C. and 8° C.) in order to be subsequently reconstituted in an adjuvant-free saline solution prior to use.

Abstract: The invention relates to murine monoclonal antibodies corresponding to monoclonal antibodies secreted by cell lines of hybridomas denominated 3G8/C11 and 7G4/A12, and which react against the antigen M of hMPV. Said antibodies do not compete with each other for the binding site for binding to the antigen, nor do they impede the simultaneous binding thereof to the antigen. Said monoclonal antibodies can be used for tests for the detection, diagnosis and/or determination of infection by hMPV.

Abstract: The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies.

Abstract: Relative displacements related to a structure are measured for use of a feedback signal in real time for the structural monitor of active and semi-active vibration. The monitors reduce structural movement caused by any source of natural or artificial vibration. A pre-stressed axial element is installed between two different points of the structure using a fixed connector and a flexible one. As the structure vibrates in response to an external “source”, a relative displacement is caused between two connecting points of the axial element, which can be measured based on the rotation ? of the flexible connector of the axial element. Discrete displacement can be obtained in real time of the whole structure where the axial element is installed. A modal monitor through active or semi-active devices can improve the structural behavior in some cases.

Abstract: The invention relates to a method for producing tolerogenic dendritic cells (tolDCs) with specific antigens, comprising the steps of: (a) culturing precursors of dendritic cells in an animal-serum-free medium, using cytokines, IL-4 and GM-CSF, in order to differentiate same in dendritic cells; (b) producing apoptotic cells; (c) culturing the dendritic cells obtained in step (b) in the presence of compounds having anti-inflammatory activity; (d) co-culturing the dendritic cells from step (d) with the apoptotic cells from step (c), such as to stimulate the endocytosis of the apoptotic cells by the dendritic cells; (e) and, by means of identification based on phenotypic evaluation, determining the production of tolerogenic dendritic cells (tolDCs) with specific antigens. The invention also relates to the tolDC cells produced with said method and to the use of said tolDCs with specific antigens in the production of a drug suitable for the treatment of systemic lupus erythematosus.

Abstract: The invention provides identification methods of specific modulators of hemichannels formed by connexin through the use of structural bioinformation methods for the calculation of the interaction energy with ligands and compositions to selectively modulate the activity of hemichannels formed by connexins. Among other aspects, the invention describes a computer-aided method, where estimating the interaction energy between ligands coming from a database of chemical compounds is possible, with a binding pocket defined by the region comprising the residues of 3-10 (NTH), 29-40 (TM1), 74-93 (TM2) of a protomer and residues 29-40 (TM1) of an adjacent protomer in connexin 26 or the equivalent residues in other connexins.

Abstract: Device for three-dimensional vibration insulation between structures or industrial equipment in general and the foundations thereof, comprising a hexagonal framework formed by six plates connected so as to pivot in relation to each other by horizontal parallel hinges, at least a spring and a damper being arranged between the plates. The device further comprises a connector arranged its series on the upper plate so as to pivot about a horizontal axis perpendicular to the axis of the hinges. The insulating system comprises a plurality of devices operating in parallel and oriented in such a way that the transverse axes thereof (defined by the hinges) converge onto a vertical axis that contains the center of gravity of the structure or equipment being insulated, in particular against high-intensity seismic activity with large displacements.

Abstract: A method and a system are for compensating optical aberrations in a telescope. The method is applicable to a telescope wherein the element for receiving a primary beam is an image acquisition device (3), and involves using an algorithm without an image processing sensor for: a) detecting optical aberrations affecting the primary focus, by analyzing the images acquired by the image acquisition device (3), and b) calculating and generating first positional correction values, by processing the detected optical aberration values. The method also includes a step c) consisting in moving, in a controlled manner, the image acquisition device (3), applying suitable control signals generated from the first positional correction values. The system is suitable for implementing the proposed method.

Abstract: The use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, to a monoclonal antibody IgG2A secreted by the cell line of 8A4/G9 hybridoma specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. The antibodies are in the pure state and do not contain any other contaminating biological material. A method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a given host is provided, including the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease. The antibody can be humanized in order to minimize the possibility of an immune response against the same in the patient.

Abstract: The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R1 is a (C1-C2) alkyl radical; R2 and R3 are radicals independently selected from the group consisting of F, CI and methyl R4 is H or OH; A is a birradical selected from the group consisting of —(CH2)n— and —(CH2)-phenyl-(CH2)—; t is an integer from 0 to 1; and n is an integer from 8 to 15, are useful for the treatment of Alzheimer's disease.

Abstract: A pharmaceutical composition is provided having an effective amount of angiotensin-(1-9) and at least one pharmaceutical acceptable carrier, excipient, stabilizer, diluent, and/or adjuvant. Also provided is a method of using the pharmaceutical composition for inhibiting and/or reducing cardiovascular remodeling.

Abstract: The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R1 is a (C1-C2) alkyl radical; R2 and R3 are radicals independently selected from the group consisting of F, Cl and methyl R4 is H or OH; A is a birradical selected from the group consisting of —(CH2)n— and —(CH2)-phenyl-(CH2)—; t is an integer from 0 to 1; and n is an integer from 8 to 15, are useful for the treatment of Alzheimer's disease.